|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Emerging genomic aberrations for which TKIs have shown impressive results in clinical trials and expansion of drug labels for approved agents are awaited include ROS1 rearrangements (1-2% of tumors, drug: crizotinib) and BRAF-V600E mutations (1-3% of tumors, drugs: vemurafenib, dafrafenib + trametinib).
|
26620497 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Significantly larger tumor size was observed in ROS1 immunohistochemistry (IHC)-negative patients compared with ROS1 IHC-positive patients.
|
27121721 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Histologically, RET and ROS1 fusion tumors share the solid signet-ring cell and mucinous cribriform pattern, as previously mentioned in the histology of ALK fusion tumors.
|
25234288 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, we employed a template method to develop the core-shell gold nanocage@manganese dioxide (AuNC@MnO<sub>2</sub>, AM) nanoparticles as tumor microenvironment responsive oxygen producers and near-infrared (NIR)-triggered reactive oxygen species (ROS) generators for oxygen-boosted immunogenic PDT against mTNBC.
|
29890364 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These findings demonstrate that activation of STAT3 and Bcl-2 and reduction of ROS contribute to the development of radioresistance in TNBC, and niclosamide acts as a potent radiosensitizer via inhibiting STAT3 and Bcl-2 and increasing ROS generation in TNBC cells and xenograft tumors.
|
29855616 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Low penetration depth of excited light, undesirable distribution of photosensitizers, severe hypoxia, and inefficient reactive oxygen species (ROS) generation in tumors, lead to the poor therapeutic effects in photodynamic therapy.
|
31566306 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A literature review identified a ROS1 fusion in 2.54% of the patients with lung adenocarcinoma and even higher frequencies in spitzoid neoplasms and inflammatory myofibroblastic tumors.
|
27256160 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Twenty-three tumor samples were ROS1 IHC-positive.
|
23400546 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, an amplified oxidative damage strategy for tumor therapy was proposed that was focused not only on the enhancement of ROS generation but also the inhibition of subsequent MTH1 enzyme activity simultaneously.
|
31262183 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Targeting ROS1 fusion proteins with the small-molecule inhibitor crizotinib is showing promise as an effective therapy in patients with NSCLC whose tumors are positive for these genetic abnormalities.
|
23719267 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Histologically, all 10 ROS1-rearranged tumors harbored an adenocarcinoma component.
|
26149475 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The recent discovery and characterization of an oncogenic ROS1 gene fusion in a subset of lung cancers has raised significant clinical interest because small molecule inhibitors may be effective to these tumors.
|
24186139 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this review, we have summarized the sources of ROS generation in cancer cells, its role in the tumor microenvironment, the possible functions of ROS and its important scavenger systems in tumor progression with special emphasis on solid tumors.
|
30905813 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Consequently endogenous ROS generation in DU-145 tumor spheroids was increased in the presence of either IA or 2-DDG, which was abolished upon coincubation with ebselen.
|
19950199 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, decreasing the intracellular glutathione (GSH) level through the -S-S-/GSH redox chemistry increases the ROS generation level both in vitro and in vivo, facilitating cytotoxic T lymphocyte (CTL) proliferation and reducing tumour growth in an aggressive B16-OVA melanoma tumour model.
|
29803106 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Some of the ALK and ROS1 rearranged tumors may also harbor coexisting EGFR mutations.
|
22661537 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Such ROS-dependent chemiluminescence of SPN allows ROS generation within a tumor to be optically monitored during the CDT process.
|
31777250 |
2020 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Patients with ROS1 gene rearrangements were younger and typically never-smokers, with the tumors all being adenocarcinomas with higher-grade architectural features and focal signet ring morphologic features (two of five).
|
27179848 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Entrectinib (RXDX-101) is a pan-ALK, TRKA, TRKB, TRKC, and ROS1 inhibitor with activity against tumors with <i>ALK</i>, <i>NTRK1</i>, <i>NTRK2</i>, <i>NTRK3</i>, and <i>ROS1</i> alterations in Phase I clinical trials in adults.
|
30425456 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Great progress has also been made regarding novel nanoparticle-mediated therapies to enhance tumor cell death via ROS generation and angiogenic inhibition.
|
28990403 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Of 19 tumors with EGFR mutations, ALK fluorescence in situ hybridization positivity, or ROS1 fluorescence in situ hybridization positivity, 18 had a PD-L1 TPS less than 50% versus only one tumor with a PD-L1 TPS of at least 50% (p = 0.0073).
|
28104537 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
ROS1 protein expression in tumor cells is 100% sensitive and 92% specific for ROS1 rearrangements by FISH.
|
23887156 |
2013 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
ROS1 rearrangements have been detected in a variety of tumors and are considered as suitable targets of anticancer therapies.
|
25231053 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
However, eIF2αP-deficient human tumor cells are highly susceptible to extrinsic ROS generated by the pro-oxidant drug doxorubicin by undergoing premature senescence.
|
24334569 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In the current study, we aimed to investigate the frequency and clinicopathologic features associated with ROS1 gene fusion and ROS1 protein expression in patients with ovarian serous carcinoma or serous borderline tumors.
|
30249502 |
2018 |